Home
About
Overview
Sharing Data
ORCID
Help
History (55)
Sleep quality outcomes after medical and surgical management of chronic rhinosinusitis.
Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients.
Pitheciidae
Electrowetting
Vintafolide: a novel targeted agent for epithelial ovarian cancer.
See All 55 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Vintafolide: a novel targeted agent for epithelial ovarian cancer.
Vintafolide: a novel targeted agent for epithelial ovarian cancer. Future Oncol. 2014 Mar; 10(4):541-8.
View in:
PubMed
subject areas
Animals
Antineoplastic Agents
Clinical Trials as Topic
Drug Evaluation, Preclinical
Female
Folic Acid
Humans
Molecular Targeted Therapy
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Treatment Outcome
Vinca Alkaloids
authors with profiles
Whitney S Graybill